[go: up one dir, main page]

WO2015012194A1 - Effet d'amélioration de fonction mâle d'hélipyrone a - Google Patents

Effet d'amélioration de fonction mâle d'hélipyrone a Download PDF

Info

Publication number
WO2015012194A1
WO2015012194A1 PCT/JP2014/069040 JP2014069040W WO2015012194A1 WO 2015012194 A1 WO2015012194 A1 WO 2015012194A1 JP 2014069040 W JP2014069040 W JP 2014069040W WO 2015012194 A1 WO2015012194 A1 WO 2015012194A1
Authority
WO
WIPO (PCT)
Prior art keywords
cavernous
pressure
pharmaceutical composition
group
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2014/069040
Other languages
English (en)
Japanese (ja)
Inventor
折戸謙介
小菅直哉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SCHOOL Corp AZABU VETERINARY MEDICINE EDUCATIONAL INSTITUTION
School Corp Azabu Veterinary Medicine Educational Inst
Original Assignee
SCHOOL Corp AZABU VETERINARY MEDICINE EDUCATIONAL INSTITUTION
School Corp Azabu Veterinary Medicine Educational Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SCHOOL Corp AZABU VETERINARY MEDICINE EDUCATIONAL INSTITUTION, School Corp Azabu Veterinary Medicine Educational Inst filed Critical SCHOOL Corp AZABU VETERINARY MEDICINE EDUCATIONAL INSTITUTION
Priority to JP2015528254A priority Critical patent/JPWO2015012194A1/ja
Publication of WO2015012194A1 publication Critical patent/WO2015012194A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to providing a compound having a male sexual function improving action.
  • erectile dysfunction Male sexual dysfunction often occurs as erectile dysfunction (erectile dysfunction, erectile dysfunction or erectile dysfunction; referred to as ED, etc.).
  • a pathological condition may be one of a combination of blockage of cavernous blood inflow due to penile artery contraction due to sympathetic nerve tension due to stress, reduction of nNOS activity, reduction of guanylate cyclase activity, enhancement of PDE5 activity, etc.
  • the penis does not erection or does not persist even after erection, making it impossible to have sexual intercourse.
  • Erectile dysfunction (ED) is thought to affect more than 150 million men worldwide, and there are predictions that the number will double by 2030.
  • PDE5 inhibitors have been found as compounds having such an effect of improving erectile dysfunction in men, and ED treatment has greatly advanced.
  • three types of erectile dysfunction drugs have been marketed so far.
  • Viagra launched in 1999 from Pfizer
  • Levitra Vehicle
  • Cialis launched from Bayer in 2004,
  • Cialis launched from Eli Lilly in 2007.
  • All of these components are identical in that the mechanism of action is a PDE5 inhibitor. Because of such a background, in this field, it is required to newly find other compounds having a cavernous body pressurization enhancing action.
  • Non-patent Document 1 helipilon A has been used as a singlet oxygen scavenger, skin aging improver, wrinkle improver, sagging improver, skin moisture content improver, whitening agent, melanin inhibitor, nitric oxide scavenger, antioxidant.
  • Patent Document 1 utilization as an adiponectin production promoter
  • Patent Document 3 utilization as a tissue fibrosis inhibitor
  • the inventors of the present invention have examined whether various sexually derived substances have an effect of improving male sexual function, and as a result, hepyrone A (3, 3), a component derived from a curry plant of the asteraceae Helixam plant.
  • hepyrone A 3, 3
  • R 1 and R 2 are each independently a hydrogen atom or a hydroxyl-protecting group, or a male sexual function comprising a compound or a pharmaceutically acceptable ester or prodrug thereof
  • Pharmaceutical compositions are provided for treating disorders, particularly erectile dysfunction (ED).
  • an example of the active ingredient of the pharmaceutical composition according to the present invention is the following formula (II): Or hepropyrone A (3,3′-methylene bis (6-ethyl-4-hydroxy-5-methyl-2H-pyran-2-one)), or a prodrug.
  • the above-mentioned pharmaceutical composition of the present invention was found to be effective for the treatment of male sexual dysfunction (especially erectile dysfunction (ED)) even when orally administered.
  • the pharmaceutical composition is orally administered.
  • the present invention relates to male sex comprising administering a compound represented by the above formula (I) or formula (II) or a pharmaceutically acceptable ester or prodrug thereof to a patient with male sexual dysfunction.
  • helipon A can be used to treat male sexual dysfunction (especially erectile dysfunction (ED)). Since it became clear, it can be developed as a new drug.
  • ED erectile dysfunction
  • the structure of the compound is different from conventional male sexual function-improving drugs, to provide a drug for the treatment of male sexual dysfunction (especially erectile dysfunction (ED)) with a different mechanism of action.
  • FIG. 1 is a diagram showing a cross-sectional schematic view of the corpus cavernosum during normal (A) and erection (B).
  • FIG. 2 is a diagram showing a molecular cascade from sexual arousal in the brain to erection of the cavernous corpus cavernosum.
  • FIG. 3 is a diagram showing an outline of a measurement system for the erection level of the cavernous corpus cavernosum.
  • the upper row schematically shows the incision site of the rat, the arrangement of tubes and electrodes for measurement, and the like when measuring using a rat.
  • the lower part shows an outline of data such as voltage, blood pressure, and cavernous pressure applied to the cavernous nerve by the measurement system.
  • FIG. 4 shows that the system for measuring the erection level of the corporal cavernous body of the present invention was able to stably measure the application of electrical stimulation and the coronary body pressurizing action in response to the application of electrical stimulation over a long period (90 minutes) under anesthesia conditions.
  • FIG. FIG. 5 shows a measurement system of penile cavernous body erection level according to the present invention, under the condition of applying electrical stimulation to the cavernous nerve, carboxymethylcellulose (CMC, solvent control group) (A) or hepyrone A (30 It is the figure which showed the cavernosal pressor action before administration and 90 minutes after administration of mg / kg (experimental group) (B).
  • CMC carboxymethylcellulose
  • B hepyrone A
  • FIG. 6 shows a measurement system of the erection level of the corpor cavernosa of the present invention, under the condition of applying electrical stimulation to the cavernous nerve, and compared with carboxymethylcellulose (CMC, solvent control group) It is the figure which showed that cavernosal pressor action by electrical stimulation was significantly enhanced by administration of 30 mg / kg, experimental group).
  • FIG. 7 is a diagram for explaining the “maximum cavernous body pressure” and “cavernous body pressure half-life” shown in this example.
  • “maximum cavernous body pressure” which is the maximum value of “cavernous body pressure for average blood pressure”
  • FIG. 8 shows the results of studying the effects of sildenafil and helipyrone A (HA) on blood pressure using the penile cavernous body erection level measurement system of the present invention. Numbers in parentheses indicate the number of animals used in the experiment.
  • FIG. 9 shows the results of examining the effect of sildenafil on the increase in cavernosal pressure caused by electrical stimulation using the system for measuring the erection level of the penile cavernous body of the present invention. Numbers in parentheses indicate the number of animals used in the experiment.
  • FIG. 9 shows the results of examining the effect of sildenafil on the increase in cavernosal pressure caused by electrical stimulation using the system for measuring the erection level of the penile cavernous body of the present invention. Numbers in parentheses indicate the number of animals used in the experiment.
  • FIG. 10 shows the results of examining the effect of helipyrone A (HA) on the increase in corpus cavernosum caused by electrical stimulation, using the penile cavernous body erection level measurement system of the present invention. Numbers in parentheses indicate the number of animals used in the experiment.
  • FIG. 11 is a diagram of the organ bus apparatus used in the example of the present invention.
  • FIG. 12 shows the results of investigating the relaxing action of helipyrone A and sildenafil on the isolated corpus cavernosum using an organ bath apparatus.
  • Figure 13 shows that helipyrone A (HA) potentiates the electrical stimulation-induced relaxation in isolated corpus cavernosum, which L-NAME suppresses this effect, and that the inhibitory effect of L-NAME is restored by L-arginine.
  • the upper figure shows the contraction-relaxation profile of the isolated corpus cavernosum, and the arrowheads indicate the time point when hepyrone A, L-NAME and L-arginine were added.
  • the lower graph is a graph showing the extension of the cavernous relaxation half-life due to the addition of heliciron A, L-NAME and L-arginine.
  • a solvent CMC
  • the present invention comprises the following formula (I): Wherein R 1 and R 2 are each independently a hydrogen atom or a hydroxyl-protecting group, or a male sexual function comprising a compound or a pharmaceutically acceptable ester or prodrug thereof Pharmaceutical compositions are provided for treating disorders, particularly erectile dysfunction (ED).
  • ED erectile dysfunction
  • the hydroxyl-protecting group is not particularly limited as long as it can stably protect the hydroxyl group during the reaction, and specifically, a biological method such as hydrolysis in vivo.
  • a protecting group that can be cleaved by chemical methods such as hydrogenolysis, hydrolysis, electrolysis and photolysis, such as formyl, acetyl, propionyl, butyryl, isobutyryl, pentanoyl , Pivaloyl, valeryl, isovaleryl, octanoyl, nonanoyl, decanoyl, 3-methylnonanoyl, 8-methylnonanoyl, 3-ethyloctanoyl, 3,7-dimethyloctanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl, hexa Decanoyl, 1-methylpentadecanoyl, 1-methyl
  • a group that forms a pharmacologically acceptable ester such as “aliphatic acyl group” and “aromatic acyl group” or “silyl group” is preferable, and acetyl, propionyl are more preferable.
  • “C 1 -C 6 alkanoyl groups” such as butyryl, isobutyryl, pentanoyl and pivaloyl; or “silyl groups” such as t-butyldimethylsilyl group and t-butyldiphenylsilyl group, particularly preferably Acetyl group, t-butyldimethylsilyl group or t-butyldiphenylsilyl group.
  • a protective group for a hydroxyl group which is a “protecting group that can be cleaved in vivo by a biological method such as hydrolysis” refers to a free acid or its acid that is cleaved by a biological method such as hydrolysis in the human body.
  • a protective group that forms a salt is determined by administering it intravenously to a laboratory animal such as a rat or mouse, examining the body fluid of the animal, and then examining the original compound or its pharmacological agent. It can be determined by the ability to detect acceptable salts.
  • protecting group for a hydroxyl group which is a “protecting group that can be cleaved by a biological method such as hydrolysis in vivo”
  • a biological method such as hydrolysis in vivo
  • formyloxymethyl, acetoxymethyl, propionyloxymethyl, butyryloxymethyl, Pivaloyloxymethyl, valeryloxymethyl isovaleryloxymethyl, hexanoyloxymethyl, 1-formyloxyethyl, 1-acetoxyethyl, 1-propionyloxyethyl, 1-butyryloxyethyl, 1-pivalo Yloxyethyl, 1-valeryloxyethyl, 1-isovaleryloxyethyl, 1-hexanoyloxyethyl, 1-formyloxypropyl, 1-acetoxypropyl, 1-propionyloxypropyl, 1-butyryloxypropyl, 1-pivaloyloxypropyl, 1-valeryloxypropyl
  • ester of the compound of the present invention examples include esters formed from alkyl groups having 1 to 6 carbon atoms. Examples of such esters include methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, s-butyl ester, t-butyl ester, pentyl ester, isopentyl ester, neopentyl ester, etc. can do.
  • an active ingredient according to the present invention that can be used in the treatment of male sexual dysfunction, particularly erectile dysfunction (ED), is the following formula (II): Or hepropyrone A (3,3′-methylene bis (6-ethyl-4-hydroxy-5-methyl-2H-pyran-2-one)), or a prodrug.
  • the active ingredient contained in this pharmaceutical composition and heliponone A having the structure of the above formula (I) is described in Esahak Ali et al. (Esahak A., et al., Phytochemistry, 1982, 21, 243-244). As described above, it is a component contained in various plants, for example, a curry plant (Helichrysum italicum) of the Asteraceae Heliksum family, and originally obtained as a component derived from a natural product.
  • a curry plant Helichrysum italicum
  • helipyrone A When helipyrone A is used as cosmetics or foods, it can be expected to suppress wrinkles, improve skin aging, photoaging, whitening agents, melanin production, antioxidant, and singlet oxygen elimination, resulting in skin aging improving agents and photoaging. It has been known that it can be used as an inhibitor, a whitening agent, a melanin production inhibitor, an antioxidant, a singlet oxygen scavenger, and a nitric oxide scavenger (WO2007 / 125832 or JP2013-060383).
  • Heripiron A used in the present invention can be extracted from a plant (for example, a curry plant of the genus Helixamaceae) or chemically synthesized.
  • a plant for example, a curry plant of the genus Helixamaceae
  • helipyrone A was provided by FANCL Corporation.
  • Heliponone A can be chemically synthesized at present and can be performed based on the literature of Esahak Ali et al. Specifically, a method for chemically synthesizing helipyrone A is known (for example, WO2007 / 125832 or JP2013-060383), and the synthesis method is outlined below.
  • compound 3 ((N-isopropenyl) -tetrahydro-1,4-oxazine) was converted to compound 4 (ethylmalonyl).
  • compound 5 represented by the following formula (III) was synthesized by reacting 81 g of ethyl malonyl chloride with methanol-ice cooling (-17 ° C to -11 ° C).
  • the reaction between Compound 3 and Compound 4 was terminated by adding 2N hydrochloric acid, and extracted with chloroform, followed by magnesium sulfate drying treatment. Next, 200 mL of toluene and 400 mL of 25% hydrochloric acid were sequentially added to the reaction solution, and the toluene layer was recovered by liquid-liquid partition. The toluene layer was washed with 400 mL of 0.1N hydrochloric acid, and after drying with magnesium sulfate, toluene was removed with a vacuum evaporator to obtain an orange oily solution. 1 kg of PPA (polyphosphoric acid) was added to this solution and cyclized at 110 ° C to 118 ° C to synthesize Compound 5.
  • PPA polyphosphoric acid
  • Compound 6 (Helipyrone A) was chemically synthesized by subjecting Compound 5 to polymerization reaction of formaldehyde in the presence of 1 N hydrochloric acid. 45.7 g of Compound 5 was dissolved in 460 mL of ethanol, and 247.81 g of formaldehyde (37%) was refluxed at 79 ° C. in the presence of 2.5 mL of concentrated hydrochloric acid to precipitate crystals. The crystals are washed with ethanol to give white crystals as the following formula (II): Helipyrone A Got.
  • Prodrug The active ingredient may be derived from a prodrug.
  • prodrugs have specific protecting groups and have no pharmacological activity per se, but for example when administered orally or parenterally they are subsequently metabolized in the body and become pharmacological. An object in which an active substance is formed. All protected derivatives and prodrugs of compounds of the invention are included within the scope of the invention.
  • the cavernous body of the cavernous penis is surrounded by a fibrous tissue called white membrane.
  • the corpus cavernosum (corpora cavernosa penis) has a vein called the cavernous sinus (or cavernous sinus) in the center. Blood flows into the cavernous sinus from the cavernous artery via the spiral artery existing under the white membrane.
  • the cavernous arteries are usually thin and do not allow much blood to flow in. As a result, blood flows into the cavernous sinus and the blood from the penetrating vein that exists between the expanded cavernous sinus and the white membrane Since the outflow is balanced as the flow rate, it maintains a constant size (see Figure 1A).
  • Smooth muscle used in the present invention means a tissue specialized for contraction, and smooth muscle consists of smooth muscle fibers (cells) existing on the wall of a hollow internal organ, and is an autonomic motor neuron. Stimulated by.
  • smooth muscle means a muscle that has a smooth appearance because it has no striated pattern. Or smooth muscle is also called involuntary muscle. Increased Ca 2+ concentration in the smooth muscle cytosol causes contraction similar to striated muscle. However, sarcoplasmic reticulum (Ca 2+ reservoir in striated muscle) is poor in smooth muscle.
  • Ca 2+ flows from both extracellular fluid and sarcoplasmic reticulum to the smooth muscle cytosol, but smooth muscle fibers do not have transverse tubules, so Ca 2+ reaches the filaments at the center of the fibers and contracts It takes longer to trigger the process. This is partly responsible for slow signs of smooth muscle and persistent contractions.
  • Contraction and relaxation A number of mechanisms regulate the contraction and relaxation of smooth muscle cells.
  • a regulatory protein called calmodulin binds to Ca 2+ in the cytosol. This slows relaxation, in addition to allowing Ca 2+ to enter the smooth muscle fibers slowly, as well as causing them to slowly move away from the muscle fibers when the excitation decays.
  • the continued presence of Ca 2+ in the cytosol provides smooth muscle tone and continuous partial contraction.
  • Smooth muscle tissue resides in hollow internal organs such as blood vessels, lung airways, stomach, intestinal gallbladder, bladder, penis and clitoral cavernous walls.
  • Penile erection causes the arteries in the penis to expand through stimulation of the cavernous nerves when the central nervous system is subjected to visual, contact, auditory, olfactory stimulation, or imaginary stimulation, It means a state where a large amount of blood flows into the cavernous sinus.
  • the thickness of the cavernous artery is regulated by the autonomic nerve, and the vascular smooth muscle of the artery wall is normally contracted by the action of the sympathetic nerve, but the contraction is stopped by the stimulation of the parasympathetic nerve at the time of erection. As a result, the artery is believed to dilate.
  • the smooth muscle of the cavernous body relaxes.
  • the cavernous artery expands and the helical artery located at the entrance to the cavernous sinus expands, the amount of blood flowing into the cavernous sinus increases rapidly, and the whole tissue expands due to the blood.
  • the penetrating vein existing between the expanded cavernous sinus and the white membrane is compressed, and the outflow of blood from the cavernous sinus to the outside is suppressed.
  • An increase in the amount of blood flowing into the cavernous sinus and a decrease in the outflow of blood from the cavernous sinus work synergistically to produce an erection (see FIG. 1B).
  • the cavernous artery contracts and the pressure on the vein is reduced, the penis returns to a relaxed state.
  • NO nitric oxide
  • NOS nitric oxide synthase
  • Treatment target When this hepyrone A is administered, the cavernous pressor action caused when the cavernous nerve is stimulated in the cavernous corpus cavernosum is enhanced. Specifically, in rats under anesthesia, hepatic nerve was stimulated while administering hepirone A into the gastrointestinal tract.
  • SD sexual dysfunction
  • vascular disease eg, vascular disease associated with hypertension or diabetes, prescription drugs, and / or mental illness such as depression.
  • Physiological factors include fear, performance anxiety and interpersonal conflict. SD causes personal pain because it impairs sexual function, reduces self-esteem, and disrupts personal relationships.
  • Erectile dysfunction ED
  • penile erectile dysfunction lat of erection itself, longer time to erection, or sexual intercourse. Such as lack of erection maintenance for a sufficiently long time).
  • compositions Composition of Pharmaceutical Compositions
  • the present invention also provides a therapeutically effective amount of a pharmaceutically effective carrier of hepyrone A or an active derivative or prodrug thereof, and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition comprising a diluent or additive (including combinations thereof). This pharmaceutical composition is for use in treating male sexual dysfunction, in particular erectile dysfunction (ED).
  • ED erectile dysfunction
  • Preservatives, stabilizers, pigments, and flavoring agents may also be included in the pharmaceutical composition.
  • preservatives include sodium benzoate, sorbic acid, and p-hydroxybenzoic acid esters.
  • Antioxidants and suspending agents can also be used.
  • heliciron A which is an active ingredient of the present invention, is a component derived from a natural product (Asteraceae genus plant, curry plant), there is a high possibility that side effects are unlikely to occur even when administered orally. Further, it has been clarified that the pharmaceutical composition of the present invention is effective for the treatment of male sexual dysfunction (especially erectile dysfunction (ED)) even when orally administered. Therefore, the pharmaceutical composition of the present invention can be formulated in a dosage form suitable for oral administration and is orally administered.
  • the active ingredient of the present invention can be administered alone, but in general, it may be mixed with, for example, a pharmacologically acceptable carrier, diluent or additive.
  • the active ingredient can be administered orally in the form of tablets, capsules, suppositories, elixirs, solutions or suspensions.
  • a solubilizing agent that assists in dissolving the fat-soluble substance, for example, methyl cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, or the like may be used.
  • the tablet may contain additives such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine, disintegrants such as starch (preferably corn starch, potato starch or tapioca starch), sodium starch glycolate, Croscarmellose sodium and certain complex silicates and granulating binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and gum arabic can be included.
  • lubricants such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included.
  • a similar type of solid composition can also be used as a filler in gelatin capsules.
  • Preferred additives in this regard include lactose, starch, cellulose, lactose or high molecular weight polyethylene glycols.
  • the active ingredients are various sweeteners or flavoring agents, coloring substances or pigments, emulsifiers and / or suspending agents, and diluents such as water, ethanol, propylene glycol, etc. And glycerin and combinations thereof.
  • Dosage level The dosage level and frequency of administration of the active ingredients of the present invention for oral administration typically can be determined by a physician. However, this dose level and frequency of administration may vary depending on a wide variety of factors such as the activity of the particular compound used, metabolic stability, and the length, age, weight, general health, sex, diet, Depending on the mode of administration and time, the rate of elimination, the combination of drugs, the severity of the particular condition, and the treatment the individual receives).
  • the active ingredient and / or pharmaceutical composition of the present invention can be administered according to a schedule of 1 to 10 times a day, for example, once or twice a day.
  • the daily dose of the active ingredient may be administered once or divided.
  • the daily oral dose can be, for example, 20 to 1000 mg, preferably 50 to 300 mg, and for example, an appropriate dose can be an amount that is effective for treating male sexual dysfunction.
  • the active ingredient can be administered at a dose of 0.01 to 30 mg / kg body weight, for example, 0.1 to 10 mg / kg, more preferably 0.1 to 1 mg / kg body weight.
  • the dosages mentioned in the present invention are typical of the average case. There are, of course, individual instances where higher or lower dosage ranges are beneficial.
  • the active ingredient can be administered at 0.01 to 10 mg / dose, for example, 0.1 to 5 mg / dose, more preferably 1 to 3 mg / dose.
  • the dosages mentioned in the present invention are typical of the average case. There are, of course, individual instances where higher or lower dosage ranges are beneficial.
  • pramipexole is administered at about 0.125-0.25 mg / dose and apomorphine is administered at about 2-3 mg / dose.
  • compositions can be formulated into pharmaceutical compositions using techniques known in the art, for example, by mixing with one or more suitable carriers, diluents or additives.
  • the present invention provides a method for treating male sexual dysfunction, particularly erectile dysfunction (ED), by administering the pharmaceutical composition or prodrug of the present invention to a patient or the like.
  • Treatment as used herein means preventing or alleviating the progression and worsening of the disease state in a mammal suffering from male sexual dysfunction, particularly erectile dysfunction (ED), thereby causing progression of the disease. And treatment aimed at preventing or mitigating exacerbations.
  • the “mammal” as a target of the treatment method of the present invention means any animal classified as a mammal, and is not particularly limited. For example, in addition to humans, pet animals such as dogs, cats, rabbits, and cattle , Livestock animals such as pigs, sheep and horses. Particularly preferred “mammals” are humans.
  • Example 1 Construction of measurement system for erection level of penile cavernous body
  • development was carried out for the purpose of constructing a measurement system for erection level of penile cavernous body.
  • As animals 11-week-old adult Wistar rats (male) were used.
  • the rat was anesthetized by intraperitoneal administration of urethane (1-1.5 g / kg), and a catheter for blood pressure and heart rate measurement was inserted into the carotid artery.
  • a tube for intraduodenal administration was inserted from the mouth to the duodenum.
  • FIG. 3B shows the result in this example obtained using this animal.
  • stimulation is applied to the cavernous nerve from data such as voltage, blood pressure, and cavernous body pressure applied to the cavernous nerve by the measurement system shown in FIG. 3B
  • the systemic blood pressure also rises in conjunction with the rise. It was revealed that the cavernous body pressure may also increase.
  • the ratio of cavernous pressure to mean blood pressure ie, cavernous pressure / mean blood pressure. became.
  • Example 2 Measurement of the cavernous body pressurizing action by the measurement system of the erection level of the corporal cavernous body of the present invention The present invention was caused when the cavernous nerve was electrically stimulated using the measurement system constructed in Example 1. An experiment was conducted with the aim of confirming that the cavernosal pressor action can be measured. In Wistar rats (male) with catheters and electrodes set in the same manner as in Example 1, blood pressure, mean blood pressure, and heart rate were measured, and before the start of the experiment and 5, 30, 60, 90 minutes after the start of the experiment. Changes in cavernosal pressure were observed after stimulation for 40 seconds under conditions of 2, 4, 8 Hz, and 5 V, respectively.
  • the cavernous body pressure is affected by the blood pressure, as shown in Example 1, the cavernous body pressure / average blood pressure was used as an index.
  • the results in this example are shown in FIG.
  • the system for measuring the erection level of the corporal corpus cavernosum of the present invention shows that the application of electrical stimulation and the corpus cavernopressor action in response to the stimulation can be stably measured over a long period (90 minutes) under anesthesia conditions. Yes. Therefore, it was shown that the model animal system presented in this example is an experimental model that can be used in experiments over a long period of time.
  • Example 3 Enhancement of cavernosal pressurization of helipyrone A This example confirms whether helipyrone A has a cavernosal pressurization enhancing action when nerve stimulation to the cavernous cavernous nerve is present.
  • An experiment was conducted for the purpose.
  • blood pressure, mean blood pressure, and heart rate were measured in Wistar rats (male) in which catheters and electrodes were set in the same manner as in Example 1, and carboxymethylcellulose (CMC, solvent control group) ( A) or cavernosal pressure when stimulated for 40 seconds under conditions of 4 Hz and 5 V before administration of Hepirone A (30 mg / kg, experimental group) (B) and 5, 30, 60, and 90 minutes after administration Changes were observed.
  • CMC carboxymethylcellulose
  • the cavernous body pressure is affected by the blood pressure, as shown in Example 1, the cavernous body pressure / average blood pressure was used as an index.
  • the results of observing the cavernous body pressure when stimulated for 40 seconds under the conditions of 4 Hz and 5 V before administration and 90 minutes after administration are shown in FIG.
  • Intraduodenal administration of CMC had no effect on the cavernosal pressor action by electrical stimulation, but hepirone A (30 mg / kg) enhanced intracavernosal pressor action by electrical stimulation.
  • CMC carboxymethylcellulose
  • FIG. 1 In this experiment, under the condition of applying electrical stimulation to the corpus cavernosum, compared with carboxymethylcellulose (CMC, solvent control group), administration of hepyrone A (30 mg / kg, experimental group) significantly increased the cavernous pressure. It was shown that the effect was enhanced.
  • Example 4 Effect of hepyrone A on the cavernosal pressure increase response by cavernosal nerve stimulation in rats Using rat, the effect of hepyrone A on the cavernous pressure etc. by cavernous nerve stimulation and the effect of sildenafil We examined while comparing.
  • Sexually matured male rats were fixed in a supine position under urethane anesthesia, and a blood pressure / heart rate measuring catheter filled with heparinized physiological saline was inserted into the carotid artery and placed.
  • a silicone tube equipped with a material administration syringe was orally inserted into the duodenum and left in place.
  • cavernous nerve running on the prostate After laparotomy, electrodes were placed on the cavernous nerve running on the prostate, and frequency-dependent cavernosal pressure increase response was observed by electrical stimulation at 4, 8 Hz and 5 V for 40 seconds (see Figure 3). ) This electrical stimulation was performed before material administration and 5, 30, 60, 90, 120 minutes after administration.
  • the cavernous body pressure was measured with a needle inserted into the cavernous body, and the cavernous body pressure / mean blood pressure (corrected cavernous body pressure) was calculated considering the effect of blood pressure.
  • the maximum value of the corrected cavernous body pressure rise reaction induced by electrical stimulation is the maximum cavernous body pressure
  • the time until the corrected cavernous body pressure recovers to half from the end of the electrical stimulation is the time of the cavernous body pressure half-life. Evaluation was made ( Figure 7).
  • FIG. 8 shows the results of examining the effects of sildenafil and helipyrone A on blood pressure.
  • sildenafil the blood pressure decreased significantly from 5 minutes after administration at 1 mg / kg, which is a dose at which the effect of electrical stimulation on the increase in cavernous pressure was observed.
  • no change in blood pressure was observed for helipyrone A.
  • sildenafil nor helipiron A affected the heart rate (data not shown).
  • FIG. 9 shows the effect of sildenafil.
  • FIG. 9 is a graph comparing the effect of sildenafil on the increase in cavernous pressure caused by electrical stimulation with distilled water as a solvent. The horizontal axis of the graph represents the time after administration.
  • maximum cavernous body pressure in both 4 Hz and 8 Hz (upper and lower graphs in FIG. 9).
  • FIG. 10 shows the results for helipyrone A.
  • “maximum cavernous pressure” significantly increased from 1 hour to 1.5 hours after administration at 4 Hz.
  • Example 5 Examination of relaxation effect of heliciron A on isolated corpus cavernosum using organ bath
  • the organ bath is to measure the contraction / relaxation response of tissues such as rat, mouse or human bladder or urethra. And a small bus to hang the tissue in (see Figure 11).
  • the isolated cancellous body vertically divided was suspended in an organ bath filled with Krebs solution (97% O 2 + 3% CO 2 , 37 ° C.), and after stabilization, contracted with phenylephrine. This specimen was used to elucidate the relaxation profiles of helipiron A and sildenafil.
  • the isolated caverns suspended in the organ bath were contracted with phenylephrine and then heripilone A was added, but even the highest concentration of 10 -4 M did not cause relaxation.
  • sildenafil caused relaxation from 10 -7 M ( Figure 12). From these results, it was suggested that sildenafil has a direct vasorelaxant effect but helipon A does not have a vasorelaxant effect.
  • helipon A can be used to treat male sexual dysfunction (especially erectile dysfunction (ED)).
  • ED erectile dysfunction
  • it can be developed as a new drug, and a new drug for male sexual dysfunction (especially erectile dysfunction (ED)) can be provided.
  • male sexual dysfunctions especially erections
  • it may be possible to provide a medicament for the treatment of dysfunction (ED).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention vise à trouver un nouveau composé qui n'a aucun effet autre qu'un effet d'augmentation de pression caverneuse, différent de compositions médicinales classiques pour traiter ou améliorer une dysfonction érectile. La présente invention concerne diverses substances dérivées de produits naturels par rapport à la présence ou l'absence d'un effet d'amélioration de fonction mâle. Par conséquent, ils ont trouvé que l'administration d'hélipyrone A (3,3'-méthylenebis(6-éthyl-4-hydroxy-5-méthyl-2H-pyran-2-one)), qui est un composant dérivé de plante de curry appartenant à l'espèce Helichrysum de la famille des Asteraceae, améliore un effet d'augmentation de pression caverneuse induite par stimulation de nerf caverneux dans le corps caverneux du pénis et accomplit ainsi la présente invention.
PCT/JP2014/069040 2013-07-22 2014-07-17 Effet d'amélioration de fonction mâle d'hélipyrone a Ceased WO2015012194A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2015528254A JPWO2015012194A1 (ja) 2013-07-22 2014-07-17 ヘリピロンａの男性性機能改善作用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013-152127 2013-07-22
JP2013152127 2013-07-22

Publications (1)

Publication Number Publication Date
WO2015012194A1 true WO2015012194A1 (fr) 2015-01-29

Family

ID=52393236

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/069040 Ceased WO2015012194A1 (fr) 2013-07-22 2014-07-17 Effet d'amélioration de fonction mâle d'hélipyrone a

Country Status (2)

Country Link
JP (1) JPWO2015012194A1 (fr)
WO (1) WO2015012194A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017043572A (ja) * 2015-08-28 2017-03-02 株式会社ファンケル ヘリピロンａを有効成分とするｂｄｎｆ産生促進剤

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007125832A1 (fr) * 2006-04-25 2007-11-08 Fancl Corporation piÉgeur d'oxygÈne singulet, agent anti-vieillissement de la peau, agent antirides, Agent anti-relÂchement, agent amÉliorant la teneur en eau de la peau, agent de blanchiment de la peau, inhibiteur de mÉlanine, piÉgeur de monoxyde d'azote ET antioxydant, chacun UTILISANT DU HELIPYRONE A
JP2013107829A (ja) * 2011-11-17 2013-06-06 Fancl Corp カレープラント抽出物を有効成分とする血流改善剤
JP2014047154A (ja) * 2012-08-30 2014-03-17 Fancl Corp ペルオキシナイトライト生成抑制剤
JP2014047160A (ja) * 2012-08-31 2014-03-17 Fancl Corp 一酸化窒素産生促進又は誘導剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007125832A1 (fr) * 2006-04-25 2007-11-08 Fancl Corporation piÉgeur d'oxygÈne singulet, agent anti-vieillissement de la peau, agent antirides, Agent anti-relÂchement, agent amÉliorant la teneur en eau de la peau, agent de blanchiment de la peau, inhibiteur de mÉlanine, piÉgeur de monoxyde d'azote ET antioxydant, chacun UTILISANT DU HELIPYRONE A
JP2013107829A (ja) * 2011-11-17 2013-06-06 Fancl Corp カレープラント抽出物を有効成分とする血流改善剤
JP2014047154A (ja) * 2012-08-30 2014-03-17 Fancl Corp ペルオキシナイトライト生成抑制剤
JP2014047160A (ja) * 2012-08-31 2014-03-17 Fancl Corp 一酸化窒素産生促進又は誘導剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ORAZIO TAGLIALATELA-SCAFATI ET AL.: "Antimicrobial Phenolics and Unusual Glycerides from Helichrysum italicum subsp. microphyllum", J NAT PROD., vol. 76, no. 3, March 2013 (2013-03-01), pages 346 - 353 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017043572A (ja) * 2015-08-28 2017-03-02 株式会社ファンケル ヘリピロンａを有効成分とするｂｄｎｆ産生促進剤

Also Published As

Publication number Publication date
JPWO2015012194A1 (ja) 2017-03-02

Similar Documents

Publication Publication Date Title
JP6391071B2 (ja) シスタチオニン−γ−リアーゼ（ＣＳＥ）阻害剤
JP5780430B2 (ja) 勃起不全の処置用のＰＤＥ５阻害剤と組み合わせたｓＧＣ刺激剤またはｓＧＣ活性化剤
JP6858716B2 (ja) 心筋ミオシン活性化剤と洞房結節Ｉｆ電流阻害剤の併用療法
ES2736007T3 (es) Agente medicinal para el tratamiento de la esclerosis lateral amiotrófica o la prevención de la progresión de una fase de la esclerosis lateral amiotrófica
CN101466435A (zh) Kw-3902在充血性心脏衰竭和急性体液超负荷患者中实现利尿作用的用途
JP2016523276A (ja) 間質性膀胱炎／膀胱痛症候群（ｉｃ／ｂｐｓ）に関連する疼痛の予防および治療のためのシグマリガンドの使用
JPH0920659A (ja) 炎症性腹部疾患のためのカッパ−アヘン製剤作働薬
EP2716302B1 (fr) Agent prophylactique ou thérapeutique pour la douleur neuropathique associée au syndrome de guillain-barré
JP2002509880A (ja) Ｉｃｕ鎮静のためのデクスメデトミジンの用途
WO2001039805A1 (fr) Coprescription pour le traitement du glaucome
JP2009539996A (ja) 腎機能障害を持つ個体における利尿改善方法
TW201313679A (zh) 吲哚氫胺酸和吲哚啉氫胺酸於治療心臟衰竭或神經損傷的用途
US11571411B2 (en) Use of a bisamide derivative of malonic acid for treating allergic and other diseases in humans and animals
WO2005049043A1 (fr) Therapie combinee comprenant de la metformine et des agents anticonvulsivants
US6844361B2 (en) Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor
TWI389907B (zh) １，４－苯並噻氮呯－１－氧化物衍生物及使用該衍生物之醫藥組成物
WO2015012194A1 (fr) Effet d'amélioration de fonction mâle d'hélipyrone a
KR20210038907A (ko) 심부전 치료를 위한 17베타-헤테로시클릴-디기탈리스 유사 화합물
JP2011519946A (ja) １−メチルニコチンアミド類似体
WO1997024333A1 (fr) Composes de prevention/traitement s'appliquant aux complications de diabetes
TW202035415A (zh) 用於治療骨關節炎的化合物
TWI859343B (zh) 用於治療心臟衰竭的具有作為SERCA2a的純或顯著純刺激劑的活性的雄烷衍生物
WO2019173505A1 (fr) Méthodes de traitement de troubles liés à la régulation glycémique
WO2004091659A1 (fr) Medicament destine a la prevention ou au traitement des maladies oculaires angiogeniques
US20030158118A1 (en) Combination of cimetidine and cysteine derivatives for treating cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14830340

Country of ref document: EP

Kind code of ref document: A1

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2015528254

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14830340

Country of ref document: EP

Kind code of ref document: A1